Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul-Aug;15(4):102534.
doi: 10.1016/j.jceh.2025.102534. Epub 2025 Feb 25.

Efficacy and Safety of Direct Oral Anticoagulants Compared to Vitamin K Antagonists for Atrial Fibrillation in Patients With Liver Cirrhosis: An Update Systematic Review and Meta-analysis

Affiliations
Review

Efficacy and Safety of Direct Oral Anticoagulants Compared to Vitamin K Antagonists for Atrial Fibrillation in Patients With Liver Cirrhosis: An Update Systematic Review and Meta-analysis

Maria C R Miranda et al. J Clin Exp Hepatol. 2025 Jul-Aug.

Abstract

Background: This meta-analysis aimed to compare the efficacy and safety of direct oral anticoagulants (DOACs) with vitamin K antagonists (VKAs) in patients with concomitant atrial fibrillation (AF) and liver cirrhosis (LC).

Methods: PubMed, Cochrane Library, Embase, Scopus, Web of Science, and China National Knowledge Infrastructure (CNKI) databases were searched for randomized clinical trials (RCTs) and non-RCTs comparing DOACs and VKAs in patients with AF and LC. Analyses were performed in R software. A random-effects model was employed to calculate the pooled hazard ratio (HR).

Results: Eleven studies encompassing 19,617 patients were included, with 9379 receiving DOACs and 10,238 receiving VKAs. DOACs were associated with a significant reduction in the incidence of major bleeding (HR 0.70; 95% CI: 0.61-0.81; P < 0.001; I2 = 0%), all-cause mortality (HR 0.87; 95% CI: 0.78-0.98; P = 0.022; I2 = 41%), and gastrointestinal bleeding (HR 0.75; 95% CI: 0.67-0.84; P < 0.001; I2 = 4%). No significant difference was observed for thromboembolic events (HR 0.86; 95% CI: 0.69-1.06; P = 0.153; I2 = 0%).

Conclusion: DOACs may be a feasible option for patients with AF and LC, demonstrating similar effectiveness to VKAs while exhibiting a better safety profile. These findings await validation by prospective studies.

Keywords: atrial fibrillation; direct oral anticoagulants; liver cirrhosis; meta-analysis; vitamin K antagonists.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

Cited by

References

    1. Hanis Z., Gregory Y.H. Lip, Lane D.A. Epidemiology of atrial fibrillation. Int J Clin Pract. 2018;72 doi: 10.1111/ijcp.13070. - DOI - PubMed
    1. Joglar José A., Chung M.K., Armbruster A.L., et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American heart association Joint committee on clinical Practice guidelines. Circulation. 2024;149 doi: 10.1161/CIR.0000000000001193. - DOI - PMC - PubMed
    1. O'Leary J.G., Greenberg C.S., Patton H.M., Caldwell S. AGA clinical Practice update: coagulation in cirrhosis. Gastroenterology. 2019;157:34–43.e1. doi: 10.1053/j.gastro.2019.03.070. - DOI - PubMed
    1. January C.T., Samuel Wann L., Calkins H., et al. AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American heart association task force on clinical Practice guidelines and the heart rhythm society in collaboration with the society of thoracic surgeons. Circulation. 2019;140 doi: 10.1161/CIR.0000000000000665. - DOI - PubMed
    1. Markus Peck-Radosavljevic Thrombocytopenia in chronic liver disease. Liver Int. 2017;37:778–793. doi: 10.1111/liv.13317. - DOI - PubMed

LinkOut - more resources